ABBV — AbbVie Inc.
$285.64+0.16%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ABBV in the TickerWise workspace.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NYSE
- Employees: 55,000
- Website: https://www.abbvie.com
Latest SEC filings for ABBV
Latest ABBV news
- BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? Read article
- AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Read article
- AbbVie sees positive late-stage results for lutikizumab in hidradenitis suppurativa Read article
- AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results Read article
- Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie Read article
- Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle Read article
- Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends Read article
- AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.